Fecal <i>Bifidobacterium</i> Serves as a Predictor of Postoperative Recurrence After Neoadjuvant Chemotherapy in Pancreatic Cancer.

ABSTRACT:

Background and aims

To date, neoadjuvant chemotherapy (NAC) is a well-accepted therapeutic strategy for patients with resectable (R) and borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC). We previously reported that the relative abundance of Bifidobacterium in the gut microbiota is associated with a more favorable pathological response to NAC in R/BR-PDAC. In the current study, we evaluated the association between pretreatment gut microbiota and postoperative prognosis in patients with R/BR-PDAC who underwent pancreatectomy after NAC.

Methods

In this prospective observational study, we analyzed 42 patients with R/BR-PDAC who underwent pancreatic resection following NAC with gemcitabine plus S-1 between 2020 and 2022 at Kansai Medical University Hospit

SUBMITTER: Takaori A 

PROVIDER: S-EPMC12546966 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature